New Study Slams Safety of GlaxoSmithKline’s Avandia Drug

LONDON, July 18 (Reuters) - The safety of GlaxoSmithKline Plc’s controversial diabetes drug Avandia was attacked in a new analysis by German researchers on Wednesday, dealing a fresh blow to the group’s second-biggest product. They found little evidence that Avandia improved the quality or length of diabetics’ lives and concluded it could actually worsen complications of the disease, after studying pooled data from 18 past trials involving 8,000 patients.

MORE ON THIS TOPIC